InsiderDB

Lobbying disclosures · Lobbying report

MCK: second_quarter 2026 lobbying report

Issues related to the pharmaceutical supply chain and drug shortages. Issues related to independent physician practices and community-based care. Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act. and S.2426, Equitable Community Access to Pharmacist Services Act. Issues related to pharmacies and patient access.

Follow MCK
Became public
Jul 20, 2026, 11:28 AM EDT
Event / period date
Not stated
Collected
Nov 10, 2026, 8:10 AM EST

Why this is connected

Legal-name match: MCKESSON CORPORATION is MCKESSON CORP (https://www.sec.gov/Archives/edgar/data/927653/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Income: $60,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/07797f6b-eb0d-4f96-86d7-eb4a9f841452/","filing_uuid":"07797f6b-eb0d-4f96-86d7-eb4a9f841452","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/07797f6b-eb0d-4f96-86d7-eb4a9f841452/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Teresa Schofield","dt_posted":"2026-07-20T11:28:28-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"607 - 14th Street NW","registrant_address_2":"Suite 750","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":320918,"url":"https://lda.gov/api/v1/registrants/320918/","house_registrant_id":39554,"name":"KOUNTOUPES DENHAM CARR & REID, LLC","description":"Federal lobbying and consulting services","address_1":"607 - 14th Street NW","address_2":"Suite 750","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NANCY HARPER MARLOW","contact_telephone":"+1 202-803-4585","dt_updated":"2026-07-22T14:29:32.717701-04:00"},"client":{"id":65247,"url":"https://lda.gov/api/v1/clients/65247/","client_id":65247,"name":"MCKESSON CORPORATION","general_description":"Health care distribution company","client_government_entity":null,"client_self_select":false,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-02-14"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the pharmaceutical supply chain and drug shortages. Issues related to independent physician practices and community-based care.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144880,"prefix":null,"prefix_display":null,"first_name":"LESLIE","nickname":null,"middle_name":null,"last_name":"ZELENKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":45200,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"DENHAM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141462,"prefix":"ms","prefix_display":"MS.","first_name":"MARY","nickname":null,"middle_name":"DEE","last_name":"BEAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":10646,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"HERSHEY","last_name":"CARR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to H.R. 3164, Ensuring Community Access to Pharmacist Services Act. and S.2426, Equitable Community Access to Pharmacist Services Act. Issues related to pharmacies and patient access.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45200,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"DENHAM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":10646,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"HERSHEY","last_name":"CARR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141462,"prefix":"ms","prefix_display":"MS.","first_name":"MARY","nickname":null,"middle_name":"DEE","last_name":"BEAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144880,"prefix":null,"prefix_display":null,"first_name":"LESLIE","nickname":null,"middle_name":null,"last_name":"ZELENKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

-0.25% MCK

Adjusted closing prices from Nov 11, 2026 to Nov 12, 2026. SPY changed -0.35% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in MCK

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.